Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis (EQUALISE)

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis.

To Learn More Contact:
Study Contact: Catherine Kim, 858 412 5302 or Identifer: NCT04128579

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up